0000950170-23-056416.txt : 20231030 0000950170-23-056416.hdr.sgml : 20231030 20231030164724 ACCESSION NUMBER: 0000950170-23-056416 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231030 ITEM INFORMATION: Other Events FILED AS OF DATE: 20231030 DATE AS OF CHANGE: 20231030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Reneo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001637715 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472309515 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40315 FILM NUMBER: 231360949 BUSINESS ADDRESS: STREET 1: 18575 JAMBOREE ROAD STREET 2: SUITE 275-S CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: (858) 283-0280 MAIL ADDRESS: STREET 1: 18575 JAMBOREE ROAD STREET 2: SUITE 275-S CITY: IRVINE STATE: CA ZIP: 92612 8-K 1 rphm-20231030.htm 8-K 8-K
false000163771500016377152023-10-302023-10-30

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2023

 

 

Reneo Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40315

47-2309515

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

18575 Jamboree Road, Suite 275-S

 

Irvine, California

 

92612

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 283-0280

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

RPHM

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01 Other Events.

On October 30, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) entered into a Common Stock Repurchase Agreement (the “Repurchase Agreement”) with vTv Therapeutics LLC (the “Selling Stockholder”). Pursuant to the Repurchase Agreement, the Company repurchased 576,443 shares of the Company’s common stock (the “Repurchased Shares”) for an aggregate purchase price of approximately $4.4 million directly from the Selling Stockholder in a private, non-underwritten transaction (the “Stock Repurchase”), at a price of $7.64 per share.

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Reneo Pharmaceuticals, Inc.

 

 

 

 

Date:

October 30, 2023

By:

/s/ Gregory J. Flesher

 

 

 

Gregory J. Flesher
President and Chief Executive Officer
(Principal Executive Officer)

 

 

 EX-101.SCH 2 rphm-20231030.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 rphm-20231030_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 rphm-20231030_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Entity Ex Transition Period Entity Ex Transition Period Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation State Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre Commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity File Number Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Security 12b Title Title of 12(b) Security Document Type Document Type XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Oct. 30, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001637715
Document Type 8-K
Document Period End Date Oct. 30, 2023
Entity Registrant Name Reneo Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40315
Entity Tax Identification Number 47-2309515
Entity Address, Address Line One 18575 Jamboree Road
Entity Address, Address Line Two Suite 275-S
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92612
City Area Code 858
Local Phone Number 283-0280
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol RPHM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 rphm-20231030_htm.xml IDEA: XBRL DOCUMENT 0001637715 2023-10-30 2023-10-30 false 0001637715 8-K 2023-10-30 Reneo Pharmaceuticals, Inc. DE 001-40315 47-2309515 18575 Jamboree Road Suite 275-S Irvine CA 92612 858 283-0280 false false false false Common stock, par value $0.0001 per share RPHM NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports rphm-20231030.htm rphm-20231030.xsd rphm-20231030_lab.xml rphm-20231030_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rphm-20231030.htm": { "nsprefix": "rphm", "nsuri": "http://www.reneopharma.com/20231030", "dts": { "inline": { "local": [ "rphm-20231030.htm" ] }, "schema": { "local": [ "rphm-20231030.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rphm-20231030_lab.xml" ] }, "presentationLink": { "local": [ "rphm-20231030_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_2f9cf8af-4a6b-47d1-9256-a9b1ac5b9ec2", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rphm-20231030.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2f9cf8af-4a6b-47d1-9256-a9b1ac5b9ec2", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rphm-20231030.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre Commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre Commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation State Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security 12b Title", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.reneopharma.com/20231030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-23-056416-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-056416-xbrl.zip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end